AVXS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AVXS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Days Inventory is also known as Days Sales of Inventory (DSI). AveXis's Average Total Inventories for the three months ended in Mar. 2018 was $0.00 Mil. AveXis's Cost of Goods Sold for the three months ended in Mar. 2018 was $0.00 Mil.
The historical rank and industry rank for AveXis's Days Inventory or its related term are showing as below:
AveXis's Days Inventory stayed the same from Mar. 2017 (0.00) to Mar. 2018 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The historical data trend for AveXis's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AveXis Annual Data | |||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | ||||||
Days Inventory | - | - | - | - | - |
AveXis Quarterly Data | |||||||||||||||
Dec13 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | |
Days Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, AveXis's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, AveXis's Days Inventory distribution charts can be found below:
* The bar in red indicates where AveXis's Days Inventory falls into.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
AveXis's Days Inventory for the fiscal year that ended in Dec. 2017 is calculated as
Days Inventory (A: Dec. 2017 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (A: Dec. 2016 ) | + | Total Inventories (A: Dec. 2017 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2017 ) | * | Days in Period |
= | ( (0 | + | 0) | / | 1 ) | / | 0 | * | 365 |
= | 0 | / | 0 | * | 365 | ||||
= | N/A |
AveXis's Days Inventory for the quarter that ended in Mar. 2018 is calculated as:
Days Inventory (Q: Mar. 2018 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (Q: Dec. 2017 ) | + | Total Inventories (Q: Mar. 2018 )) | / | count ) | / | Cost of Goods Sold (Q: Mar. 2018 ) | * | Days in Period |
= | ( (0 | + | 0) | / | 1 ) | / | 0 | * | 365 / 4 |
= | 0 | / | 0 | * | 365 / 4 | ||||
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AveXis (NAS:AVXS) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
AveXis's Inventory Turnover for the three months ended in Mar. 2018 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
AveXis's Inventory to Revenue for the three months ended in Mar. 2018 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 0 | / | 0 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Thank you for viewing the detailed overview of AveXis's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Sean P. Nolan | director, officer: President & CEO | C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005 |
Session R.a. Ii | officer: Sr. VP, Corp Strategy | C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015 |
Paul B Manning | director, other: Former 10% Owner | 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902 |
Sukumar Nagendran | officer: Sr. VP & Chief Medical Officer | C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015 |
Frank Verwiel | director | C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005 |
James J Litalien | officer: SrVP/Chief Reg&Quality Officer | C/O SOMAXON PHARMACEUTICALS, INC., 3721 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO CA 92130 |
Daniel G Welch | director | 4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707 |
Rick Modi | officer: Chief Business Officer | C/O AVEXIS INC, 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015 |
Phillip B. Donenberg | officer: Chief Financial Officer | C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015 |
Joao Md Siffert | director | 20 ENTERPRISE, SUITE 200, ALISO VIEJO CA 92656 |
Ag Novartis | 10 percent owner | LICHTSTRASSE 35, BASEL V8 CH 4056 |
Bong Y Koh | director | 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018 |
Terrence C Kearney | director | IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045 |
Deerfield International Master Fund, L.p. | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
James E Flynn | director, 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
From GuruFocus
By PRNewswire PRNewswire • 04-12-2018
By Marketwired Marketwired • 04-25-2018
By PRNewswire PRNewswire • 04-19-2018
By Marketwired Marketwired • 04-25-2018
By Yamil Berard Yamil Berard • 05-02-2018
By Marketwired Marketwired • 04-19-2018
By Marketwired Marketwired • 04-09-2018
By Marketwired Marketwired • 05-01-2018
By PRNewswire PRNewswire • 04-19-2018
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.